Top 5 Most-Read Evidence-Based Oncology™ Articles in 2025

Policy, precision medicine, and new ways of delivering therapeutics were popular topics in 2025 among readers of Evidence-Based Oncology™ (EBO), the multistakeholder cancer care publication of The American Journal of Managed Care^®(AJMC^®).

Here are the top 5 articles that appeared in EBO during 2025:

5. How In Vivo CAR T-Cell Therapies Could Rewrite the Cancer Care Playbook

Regular EBO contributor Ryan Flinn was ahead of the curve in August, when he gave readers a comprehensive overview of the race to develop this new type of therapy in which the cancer-fighting treatment is created within the body. His piece reviews both the science and the deal-making that unfolded throughout 2025 as small biotechs searched for partners and financing to be the first to deliver a commercial product. The breakthrough came December 9, when the late-breaking session of the American Society of Hematology featured data for 4 patients with relapsed/refractory multiple myeloma who were treated with Kelonia Therapeutics’ investigational therapy.

Read the article here.

4. On the Path to Greater Precision in Treating Multiple Myeloma

This overview of the current research pipeline kicked off a special multipart EBO cover package on multiple myeloma, which appeared around FDA approvals and key updates at the European Hematology Association. The article, featuring an interview with Hearn Jay Cho, MD, PhD, of the Multiple Myeloma Research Foundation, addresses today’s questions about how to sequence the bumper crop of myeloma therapies, the potential for individualized therapies thanks to artificial intelligence, and the quest to move treatment into earlier phases, before full-blown myeloma arrives. Finally, the article discusses the debate over population-level screening for the disease.

Read the full article here.

3. Trump’s Stance Doesn’t End Need for Diversity in Clinical Trials

One of the most divisive policy issues of 2025 has been the Trump administration's mandate to unravel health equity goals, including canceling funding for research focused on historically underrepresented populations. At the FDA, this means legal requirements that clinical trials reflect the affected populations are in limbo. This article in EBO features experts describing why these requirements are needed and how all of health care would benefit from diversity in trials.

Read the article here.

2. Will the Coming Radiopharmaceutical Wave Reach More Patients With Cancer?

This article in the April issue of EBO reviewed scientific and business milestones fueling growth in radiopharmaceuticals, a drug class that pinpoints delivery of radionuclides to targeted lesions to diagnose and treat multiple diseases. In cancer care, radioligand therapy has gained notice as the need rises for treatments in refractory tumor types that do not respond to existing therapies. Later in 2025, a major trial in prostate cancer presented at the European Society for Medical Oncology highlighted the benefits of combining lutetium (177Lu) vipivotide tetraxetan (Pluvicto; Novartis) with androgen deprivation therapy and androgen receptor pathway inhibitor therapy.

Read the article here.

1. Will Subcutaneous PD-1/PD-L1 Inhibitors Be a Game Changer?

During 2025, Bristol Myers Squibb rolled out the subcutaneous formulation of nivolumab (Opdivo), and in September, the FDA approved the subcutaneous version of pembrolizumab (Keytruda; Merck). Faster delivery of the world’s top-selling cancer drug would seem a home run, correct? Not so fast, say some experts who spoke with EBO. A drug delivery change of that scale has a cost, and not every clinic wants to absorb it. Others say patient preferences are what matter. This was one of the biggest managed care stories of the year, not just in cancer care.

Read the article here.